SCHEMBL6283587

SCHEMBL6283587

CC(C)(C)OC(=O)CN1CCN(CC(=O)O)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
CYP2D6 P10635 3/20 0.47
CYP2C19 P33261 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP2C9 P11712 2/20 0.47
POLB P06746 1/20 0.47
CYP3A4 P08684 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
RECQL P46063 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP1A2 P05177 2/20 0.43
PLA2G10 O15496 2/20 0.43
PLA2G5 P39877 2/20 0.43
SCN9A Q15858 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282329 0.93 PLA2G10 (0.47) LMNACYP2D6CYP2C19KMT2ACYP2C9
SCHEMBL6361822 0.84 PLA2G10 (0.41) LMNACYP2D6CYP2C19KMT2ACYP2C9
SCHEMBL3591635 0.83 PLA2G10 (0.49) LMNACYP2D6CYP2C19KMT2ACYP2C9
SCHEMBL6283002 0.81 CYP2D6 (0.65) LMNACYP2D6CYP2C19KMT2ACYP2C9
SCHEMBL19962102 0.80 CYP2D6 (0.66) LMNACYP2D6CYP2C19KMT2ACYP2C9
SCHEMBL3588482 0.78 SCN9A (0.53) CYP2D6CYP2C19KMT2ACYP2C9POLB
SCHEMBL8916277 0.78 PLA2G10 (0.47) KMT2AKDM4EALDH1A1PLA2G10PLA2G5
SCHEMBL30047511 0.77 TP53 (0.47) LMNAPLA2G10PLA2G5ACE
SCHEMBL20571667 0.77 GAA (0.47) KMT2APOLBKDM4EALDH1A1PLA2G10
SCHEMBL8174531 0.76 PLA2G10 (0.41) KMT2AKDM4EALDH1A1CYP1A2PLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852744-B2 Pyrrolidine derivatives and their use as chymase inhibitor DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2005-02-08 US disclosed
US-6835714-B1 Heterocyclic compounds, intermediates thereof and elastase inhibitors DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-28 US disclosed
US-20040102384-A1 Pyrrolidine derivatives and their use as chymase inhibitor DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-05-27 US disclosed
EP-1157998-B1 HETEROCYCLIC COMPOUNDS, INTERMEDIATES THEREOF AND ELASTASE INHIBITORS DAINIPPON PHARMACEUTICAL CO (JP) 2004-02-11 EP disclosed
EP-1313730-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR Dainippon Pharmaceutical Co., Ltd. (JP) 2003-05-28 EP disclosed
WO-2002018378-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2002-03-07 WO disclosed
EP-1157998-A1 HETEROCYCLIC COMPOUNDS, INTERMEDIATES THEREOF AND ELASTASE INHIBITORS Dainippon Pharmaceutical Co., Ltd. (JP) 2001-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102384-A1 Pyrrolidine derivatives and their use as chymase inhibitor CMA1, CTRL, TPSD1 LMNA 3440/4885CYP2D6 3378/4885CYP2C19 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.